RU2015115634A - Фармацевтический состав, содержащий соединения тиенотриазолодиазепина - Google Patents
Фармацевтический состав, содержащий соединения тиенотриазолодиазепина Download PDFInfo
- Publication number
- RU2015115634A RU2015115634A RU2015115634A RU2015115634A RU2015115634A RU 2015115634 A RU2015115634 A RU 2015115634A RU 2015115634 A RU2015115634 A RU 2015115634A RU 2015115634 A RU2015115634 A RU 2015115634A RU 2015115634 A RU2015115634 A RU 2015115634A
- Authority
- RU
- Russia
- Prior art keywords
- solid dispersion
- dispersion according
- thienotriazolodiazepine
- formula
- paragraphs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 239000007962 solid dispersion Substances 0.000 claims abstract 50
- 229920000642 polymer Polymers 0.000 claims abstract 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 6
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims abstract 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- -1 C-alkoxy Chemical group 0.000 claims abstract 2
- CIGIVOUJMBTYHQ-MHZLTWQESA-N CC1=C(SC2=C1C(=N[C@@](C3=NN=C(N23)C)(C)OC(=O)C)C4=CC=C(C=C4)C5=CC=CC(=C5)C#N)C Chemical compound CC1=C(SC2=C1C(=N[C@@](C3=NN=C(N23)C)(C)OC(=O)C)C4=CC=C(C=C4)C5=CC=CC(=C5)C#N)C CIGIVOUJMBTYHQ-MHZLTWQESA-N 0.000 claims abstract 2
- HRZVGSMEZUTAPI-LJAQVGFWSA-N CC1=C(SC2=C1C(=N[C@@](C3=NN=C(N23)C)(C)OC(=O)C)C4=CC=C(C=C4)NC(=O)CCC5=CC=CC=C5)C Chemical compound CC1=C(SC2=C1C(=N[C@@](C3=NN=C(N23)C)(C)OC(=O)C)C4=CC=C(C=C4)NC(=O)CCC5=CC=CC=C5)C HRZVGSMEZUTAPI-LJAQVGFWSA-N 0.000 claims abstract 2
- HJDPCFKOBODCAL-SANMLTNESA-N CC1=C(SC2=C1C(=N[C@@](C3=NN=C(N23)C)(C)OC(=O)C)C4=CC=C(C=C4)NC5=CC=CC=C5)C Chemical compound CC1=C(SC2=C1C(=N[C@@](C3=NN=C(N23)C)(C)OC(=O)C)C4=CC=C(C=C4)NC5=CC=CC=C5)C HJDPCFKOBODCAL-SANMLTNESA-N 0.000 claims abstract 2
- 150000004683 dihydrates Chemical class 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 238000001694 spray drying Methods 0.000 claims abstract 2
- 238000000338 in vitro Methods 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 230000009477 glass transition Effects 0.000 claims 2
- 229960003943 hypromellose Drugs 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707465P | 2012-09-28 | 2012-09-28 | |
| US61/707,465 | 2012-09-28 | ||
| US201361782882P | 2013-03-14 | 2013-03-14 | |
| US61/782,882 | 2013-03-14 | ||
| US201361831811P | 2013-06-06 | 2013-06-06 | |
| US61/831,811 | 2013-06-06 | ||
| PCT/IB2013/003026 WO2014068402A2 (en) | 2012-09-28 | 2013-09-27 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015115634A true RU2015115634A (ru) | 2016-11-20 |
Family
ID=50475880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015115634A RU2015115634A (ru) | 2012-09-28 | 2013-09-27 | Фармацевтический состав, содержащий соединения тиенотриазолодиазепина |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140107107A1 (https=) |
| EP (1) | EP2900221B1 (https=) |
| JP (1) | JP2015531365A (https=) |
| KR (1) | KR20150100613A (https=) |
| CN (1) | CN104968334B (https=) |
| AU (1) | AU2013340483B2 (https=) |
| BR (1) | BR112015006537A2 (https=) |
| CA (1) | CA2885944A1 (https=) |
| HK (2) | HK1210434A1 (https=) |
| IN (1) | IN2015DN03135A (https=) |
| MX (1) | MX2015003771A (https=) |
| RU (1) | RU2015115634A (https=) |
| WO (1) | WO2014068402A2 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| CN106029077A (zh) | 2013-08-01 | 2016-10-12 | 翁科埃斯克斯有限公司 | 包含噻吩并三唑并二氮杂卓化合物的药物制剂 |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| WO2015018523A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
| JP2016529246A (ja) * | 2013-08-06 | 2016-09-23 | オンコエシックス ゲーエムベーハー | Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| CN105960239A (zh) * | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| US20170095484A1 (en) * | 2014-05-02 | 2017-04-06 | Oncoethix Gmbh | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
| EP3137085A4 (en) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
| WO2015168587A1 (en) * | 2014-05-02 | 2015-11-05 | Oncoethix Sa | Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds |
| WO2015169953A1 (en) * | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
| AU2015257658A1 (en) * | 2014-05-08 | 2016-11-10 | Oncoethix Gmbh | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
| BR112016029012A2 (pt) | 2014-06-13 | 2017-08-22 | Oncoethix Gmbh | método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina |
| KR20170037670A (ko) * | 2014-08-19 | 2017-04-04 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법 |
| US20170281642A1 (en) * | 2014-08-28 | 2017-10-05 | Oncoethix Gmbh | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| KR20170068597A (ko) * | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
| CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| EP3347021A4 (en) | 2015-09-11 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| AU2016370846B2 (en) | 2015-12-18 | 2022-08-25 | Ignyta, Inc. | Combinations for the treatment of cancer |
| WO2017121806A1 (en) * | 2016-01-15 | 2017-07-20 | Sandoz Ag | Pharmaceutical composition of selexipag |
| EP3192502A1 (en) * | 2016-01-15 | 2017-07-19 | Sandoz Ag | Pharmaceutical composition of selexipag |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| KR102718538B1 (ko) | 2017-07-19 | 2024-10-21 | 이그니타, 인코포레이티드 | 엔트렉티닙을 포함하는 약학적 조성물 |
| CN111225662B (zh) * | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
| US20210038602A1 (en) * | 2018-01-25 | 2021-02-11 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia |
| JP7812785B2 (ja) * | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2022034914A1 (ja) * | 2020-08-13 | 2022-02-17 | カルナバイオサイエンス株式会社 | 易溶性固形製剤およびその製法 |
| DK4245298T3 (en) * | 2020-12-18 | 2026-03-30 | Daewoong Pharmaceutical Co Ltd | Hidtil ukendt formulering til oral administration, som omfatter 1-(5-(2,4-difluorphenyl)-1-((3-fluorphenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamin |
| CN116098870B (zh) * | 2023-04-10 | 2023-07-25 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的固体分散体及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109037C (zh) * | 1996-09-13 | 2003-05-21 | 三菱制药株式会社 | 噻吩并－三唑并二氮杂䓬化合物及其医药用途 |
| WO2001095912A1 (fr) * | 2000-06-16 | 2001-12-20 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| US8591944B2 (en) * | 2011-03-08 | 2013-11-26 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
-
2013
- 2013-09-27 JP JP2015533717A patent/JP2015531365A/ja not_active Ceased
- 2013-09-27 WO PCT/IB2013/003026 patent/WO2014068402A2/en not_active Ceased
- 2013-09-27 US US14/040,134 patent/US20140107107A1/en not_active Abandoned
- 2013-09-27 KR KR1020157009117A patent/KR20150100613A/ko not_active Ceased
- 2013-09-27 RU RU2015115634A patent/RU2015115634A/ru unknown
- 2013-09-27 BR BR112015006537A patent/BR112015006537A2/pt not_active Application Discontinuation
- 2013-09-27 AU AU2013340483A patent/AU2013340483B2/en not_active Ceased
- 2013-09-27 HK HK15111309.6A patent/HK1210434A1/xx unknown
- 2013-09-27 CA CA2885944A patent/CA2885944A1/en not_active Abandoned
- 2013-09-27 CN CN201380061396.4A patent/CN104968334B/zh not_active Expired - Fee Related
- 2013-09-27 EP EP13848127.0A patent/EP2900221B1/en not_active Not-in-force
- 2013-09-27 HK HK15112002.4A patent/HK1211209A1/xx unknown
- 2013-09-27 IN IN3135DEN2015 patent/IN2015DN03135A/en unknown
- 2013-09-27 MX MX2015003771A patent/MX2015003771A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150100613A (ko) | 2015-09-02 |
| HK1210434A1 (en) | 2016-04-22 |
| BR112015006537A2 (pt) | 2017-07-04 |
| EP2900221A2 (en) | 2015-08-05 |
| WO2014068402A3 (en) | 2014-10-16 |
| CN104968334B (zh) | 2018-09-14 |
| JP2015531365A (ja) | 2015-11-02 |
| EP2900221B1 (en) | 2019-03-06 |
| WO2014068402A2 (en) | 2014-05-08 |
| MX2015003771A (es) | 2016-03-04 |
| US20140107107A1 (en) | 2014-04-17 |
| IN2015DN03135A (https=) | 2015-10-02 |
| CN104968334A (zh) | 2015-10-07 |
| CA2885944A1 (en) | 2014-05-08 |
| AU2013340483B2 (en) | 2018-01-18 |
| AU2013340483A1 (en) | 2015-04-23 |
| HK1211209A1 (en) | 2016-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015115634A (ru) | Фармацевтический состав, содержащий соединения тиенотриазолодиазепина | |
| JP2015531365A5 (https=) | ||
| HRP20200341T1 (hr) | Bromodomenski (bet) inhibitori | |
| JP7051638B2 (ja) | エスシタロプラム医薬組成物 | |
| RU2015116953A (ru) | Новые соединения | |
| ES2647586T3 (es) | Compuesto antiinflamatorio que tiene actividad inhibidora contra múltiples tirosina cinasas, y composición farmacéutica que contiene el mismo | |
| JP2017519727A5 (https=) | ||
| AU2017227929A1 (en) | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | |
| RU2014127142A (ru) | Фармацевтическая композиция с улучшенной биодоступностью для высокоплавкого гидрофобного соединения | |
| ME02913B (me) | Čvrsta disperzija | |
| RU2579745C2 (ru) | Твердая дисперсия толваптана и способ ее получения | |
| FI3263110T3 (fi) | Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita | |
| ES2638420T3 (es) | Composición sólida de sal de aminocarboxilato | |
| RU2017100921A (ru) | Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина | |
| CA2947593A1 (en) | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds | |
| HRP20190936T1 (hr) | Amorfni letermovir i njegove krute farmaceutske formulacije za oralnu primjenu | |
| RU2015135722A (ru) | Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение | |
| JP2017519727A (ja) | チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 | |
| RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor | |
| UA123914C2 (uk) | Фармацевтичні комбінації для лікування раку | |
| JP2017517579A5 (https=) | ||
| WO2015018520A1 (en) | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma | |
| JP2014524449A5 (https=) | ||
| EP3027194A1 (en) | Pharmaceutical formulation containing thienotriazolodiazepine compounds | |
| WO2020261195A1 (en) | Substantially pure venetoclax and amorphous venetoclax in a free drug particulate form |